Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins

Merck should have included risk findings from the VIGOR study when promoting Vioxx to physicians before the data was added to labeling, FDA Office of New Drugs Director John Jenkins told a congressional hearing May 5